Hereditary spherocytosis (HS) and hereditary hemolytic anemias

What changes during this transition

Hereditary spherocytosis is the most common inherited hemolytic anemia in Northern European populations at roughly 1 in 2,000 to 1 in 5,000 prevalence, with autosomal dominant inheritance in the majority of cases and autosomal recessive inheritance in a minority. The disease is caused by mutations in genes encoding red cell membrane-skeleton vertical-interaction proteins: ANK1 (ankyrin, the most common dominant cause), SPTB (β-spectrin), SPTA1 (α-spectrin), SLC4A1 (band 3, the second most common), and EPB42 (protein 4.2). The shared mechanism is disrupted vertical interaction between the lipid bilayer and the underlying spectrin-based membrane skeleton, producing membrane vesiculation and the characteristic spherocyte morphology — a less deformable cell that is selectively retained and destroyed in the splenic cords. Clinical severity is variable: mild HS may not manifest until adulthood and may be diagnosed incidentally during workup for unrelated indications; moderate HS produces chronic hemolytic anemia, jaundice, and splenomegaly through childhood and adolescence; severe HS (often autosomal recessive) presents in infancy with transfusion dependence. Across all severities, the load-bearing clinical features are hemolytic anemia, jaundice (which can present as severe neonatal hyperbilirubinemia and is a leading cause of neonatal jaundice requiring exchange transfusion in some populations), splenomegaly from chronic red-cell trapping and destruction, pigment gallstones from chronic bilirubin overproduction, parvovirus B19-triggered transient red cell aplasia (aplastic crisis — the dominant red-flag exacerbation), and folate-deficiency-driven megaloblastic crisis when folic acid supplementation lapses. The diagnostic landscape modernized over the past two decades: the EMA (eosin-5-maleimide) binding test by flow cytometry has displaced the older osmotic fragility test as the preferred diagnostic, with cryohemolysis and genetic testing reserved for severe, atypical, or syndromic cases. Standard-of-care has not changed in shape since 19th-century recognition of splenectomy as curative: splenectomy resolves the anemia and halts splenic destruction in moderate-to-severe HS, but the modern shift has been toward partial splenectomy in children (preserving some splenic immune function while reducing red-cell destruction) and a strong reluctance to splenectomize children under 5 years because of post-splenectomy sepsis risk in that age group. Pre-splenectomy pneumococcal, meningococcal, and Hib vaccination is non-negotiable, and post-splenectomy antibiotic prophylaxis is standard in pediatric patients and many adults. Folic acid supplementation is standard. Transfusions support severe HS and aplastic crises. Cholecystectomy for symptomatic pigment gallstones is frequently combined with splenectomy. Parvovirus B19 monitoring during exposure windows is the leading aplastic-crisis-prevention conversation. The editorially current disease-modifying conversation is mitapivat (Pyrukynd, Agios Pharmaceuticals), a pyruvate kinase activator FDA-approved in February 2022 for pyruvate kinase (PK) deficiency, with expanded indication being evaluated in Phase 3 trials for HS and thalassemia (ENERGIZE-T in thalassemia). The broader red cell membrane disorder family (hereditary elliptocytosis HE, hereditary pyropoikilocytosis HPP, hereditary stomatocytosis in overhydrated and dehydrated subtypes) and the hereditary enzyme disorder family (G6PD deficiency at ~400M worldwide prevalence with X-linked inheritance and Mediterranean / African / Asian heritage concentration, PK deficiency, glucose-phosphate isomerase deficiency) form the editorial cluster this trigger sits in. Multi-jurisdictional reality: HS prevalence concentrates in Northern European Anglo-Saxon populations as a founder effect, but the disease is documented in African, Middle Eastern, and Asian populations. No peptide in the Juno library has a discovery-card-defensible HS case. BPC-157 reaches the population through the 'gut healing' and 'tissue repair' framing, with the pro-angiogenic VEGF / NO mechanism stacking against splenomegaly biology in the pre-splenectomy population and SC bleed-risk variable across severity tiers, plus a post-splenectomy infection-risk surveillance overlay. NMN reaches the population through the general-aging channel in the aging-HS demographic. The GH-axis trio surfaces a rare pediatric-HS growth-velocity question from severe untreated disease where disease control via age-appropriate splenectomy and folic acid is the actual lever, with tesamorelin Rule 6 non-propagation sharpest (HIV-LD FDA label does not extend to a hereditary red cell membrane disorder). Semaglutide is the coordination-of-care conversation for obesity in HS patients with the load-bearing post-splenectomy infection-risk surveillance overlay and the HS-pigment-gallstone-stacks-with-GLP-1-gallstone-risk reframing. Ninetieth deliberate non-elevation.